The latest news, stories and exciting findings from across the Oxford cancer research community
Unique Clinical Imaging Dataset Released for Artificial Intelligence Research to Accelerate Diagnosis of Prostate Cancer
23 September 2022
The National Cancer Imaging Translational Accelerator (NCITA) in partnership with the ReIMAGINE Consortium have announced the release of a unique clinical imaging dataset from the Prostate MRI Imaging Study (PROMIS)).
Researchers describe how cancer cells can defend themselves from the consequences of certain genetic defects
20 September 2022
Swietach Group scientists have identified a rescue mechanism that allows cancers to overcome the consequences of inactivating mutations in critically important genes
8 September 2022
Dr Francesco Boccellato wins a CRUK Early Detection and Diagnosis primer award to study tissue shape changes in the pre-cancerous stomach conditions, atrophic gastritis and intestinal metaplasia
23 August 2022
In this blog, current MB-DPhil student Holly shares her experience of intercalating a DPhil within her medical undergraduate qualification
11 August 2022
Researchers from the University of Oxford, KTH Royal Institute of Technology, Science for Life Laboratory, and the Karolinska Institutet, Solna, Sweden, have found that individual prostate tumours contain a previously unknown range of genetic variation.
First patient diagnosed earlier using liquid biopsy technology as part of the AI-REAL programme in sub-Saharan Africa
8 August 2022
The AI-REAL programme led by Professor Anna Schuh and research teams in Tanzania and Uganda is improving the early detection and outcomes of childhood lymphoma in the region by increasing the speed and precision of diagnosis.
5 August 2022
The Leedham lab have developed a new tool that assesses the relative enrichment of two main types of cancer stem cells in colorectal cancer, which may help to guide therapy selection in the future.
4 August 2022
Weight loss is a sign of undiagnosed cancer regardless of the interval over which it occurs.
3 August 2022
Substantial disagreement in individual risk prediction was found between different polygenic risk scores for breast cancer, hypertension and dementia using genotyping data from the UK Biobank.
20 July 2022
A large population-level assessment reveals third dose COVID-19 vaccination is effective for most patients with cancer, but effectiveness is lower than in the general population, particularly in patients who have undergone recent chemotherapy and those with lymphoma.
6 July 2022
Congratulations to Ivan Ahel, Adrian Hill and Yang Shi on their election to the membership of the European Molecular Biology Organization (EMBO)
28 June 2022
Body mass index, blood tests, comorbidities and medication use are temporally associated with cancer risk in the three years before a pancreatic cancer diagnosis.
23 June 2022
New, genetics and blood-based study links testosterone and insulin-like growth factor hormones to aggressive prostate cancer for the first time.
25 May 2022
The SELINA study will recruit patients with early liver cancers as part of the DeLIVER programme aiming to detect liver cancer earlier.
Population-scale study highlights ongoing risk of COVID-19 in some cancer patients despite vaccination
24 May 2022
COVID-19 vaccination is effective in most cancer patients, but the level of protection against COVID-19 infection, hospitalisation and death offered by the vaccine is less than in the general population and vaccine effectiveness wanes more quickly.
17 May 2022
Professor Julia Hippisley-Cox and Dr Tingting Zhu win funding for their collaborative project on novel test technologies for patient triage in primary care.
6 May 2022
The first major study to investigate dairy consumption and cancer risk in Chinese adults found that greater intake was associated with higher risks of liver cancer and female breast cancer.
5 May 2022
A new Oxford study finds that greater body fat (adiposity) may increase the risk of dying from prostate cancer by up to 10%.
4 May 2022
The awardees from the 2021 round of the CRUK Oxford Centre Development fund have been announced. Read about what research they will be undertaking.
3 May 2022
Dr Daniel Hughes and colleagues identify NUDT15 as a potential biomarker for pancreatic cancer recurrence following surgery.